Fate Therapeutics, Inc. (FATE) Financial Statements
Fate Therapeutics, Inc. (FATE) reported trailing twelve-month revenue of $6.5M (down 23.4% year on year) and net income of -$126.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$105.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FATEFate Therapeutics, Inc.Follow FATE — free
—
Price chart with a free account
- Market cap
- 252.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2015 Dec 15 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0 | 2.4 | 4.7 | 10.7 | 31.4 | 55.8 | 96.3 | 63.5 | 13.6 | 6.6 | 6.5 | |
| Research & development | 12.0 | 19.9 | 56.0 | 87.8 | 125.6 | 215.5 | 320.5 | 172.6 | 135.0 | 107.8 | 100.4 | |
| Operating income | -17.7 | -27.8 | -67.1 | -100.7 | -128.1 | -217.0 | -308.4 | -190.5 | -210.3 | -147.7 | -133.6 | |
| Pre-tax income | -20.9 | -30.0 | -66.6 | -98.1 | -173.4 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -126.0 | |
| Income tax | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -20.9 | -30.0 | -66.6 | -98.1 | -173.4 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -126.0 | |
| Diluted EPS ($) | -3.54 | -1.18 | -1.19 | -1.44 | -2.10 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | -1.05 | |
| Diluted shares (mn) | — | — | — | — | — | — | 96.8 | 98.4 | 113.7 | 118.8 | — |
USD millions · SEC XBRL
Fate Therapeutics, Inc. — questions
- What is Fate Therapeutics, Inc.'s revenue?
- $6.5M over the twelve months to 2026-06-30, down 23.4% year on year, from its 10-Q and 10-K filings.
- What is Fate Therapeutics, Inc.'s net income?
- -$126.0M over the twelve months to 2026-06-30.
- What is Fate Therapeutics, Inc.'s free cash flow?
- -$105.6M over the twelve months to 2026-06-30.
- What are Fate Therapeutics, Inc.'s diluted earnings per share?
- $-1.05 over the twelve months to 2026-06-30.
Every figure on this page comes from Fate Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.